JERUSALEM, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced new data from the Company’s expanding central nervous system (CNS) portfolio will be featured at the 64th American Academy of Neurology (AAN) Annual Meeting in New Orleans, LA, April 21-28, 2012. Thirty abstracts will highlight data on multiple innovative marketed and investigational therapies, including the market-leading treatment for relapsing-remitting multiple sclerosis (RRMS), COPAXONE® (glatiramer acetate injection); the investigational RRMS oral therapy laquinimod; AZILECT® (rasagiline tablets), a MAO-B inhibitor for the treatment of Parkinson’s disease; and NUVIGIL® (armodafinil) Tablets [C-IV], used to improve wakefulness in adults who experience excessive sleepiness (ES) due to shift work disorder (SWD), treated obstructive sleep apnea (OSA), or narcolepsy.
